BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst to Report Third Quarter 2026 Financial Results on November 4

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsEarnings

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026. BioCryst management will host a conference call and webcast at 8:30

Related news

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

AGIOAgios Pharmaceuticals, Inc.2026-10-08 11:00 EST

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

CAPRCapricor Therapeutics2026-08-10 12:30 EST

Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13

ETONEton Pharmaceuticals2026-08-03 10:50 EST

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

ETONEton Pharmaceuticals2026-08-13 20:05 EST

Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results

MNPRMonopar2026-08-12 13:30 EST

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

BCRXBioCryst Pharmaceuticals2026-10-05 11:00 EST

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

BCRXBioCryst Pharmaceuticals2026-08-05 11:00 EST

BioCryst Reports Second Quarter 2026 Financial Results

Stock data

Close
7.75 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States